Tag: drug development

Company News: Anergis Appoints Dr. Vanya Beltrami as Director Product Development

– Former Merck Serono Director brings strong expertise in drug development, product launches and life cycle management –

Anergis, a company discovering and developing proprietary allergy vaccines, today announced that Vanya Beltrami, PhD, has joined the company as Director Product Development.

Dr. Beltrami brings over 20 years of experience in the pharmaceutical industry with Ares-Serono, Laboratoires Serono SA and Merck Serono SA, where he held several positions with direct product development responsibility (e.g. somatropin), acting as final dosage forms project director and manufacturing product director. Most recently, he was Global Product Team Leader at the Global Product Unit Endocrinology, where he substantially expanded his cross-functional pharmaceutical development experience.

Dr. Beltrami has a long-standing track record in drug product and medical devices development as well as drug launches in multiple countries. His expertise also includes the life cycle management of a brand product generating € 250 M sales per year. Vanya Beltrami was trained as a pharmacist and holds a PhD in Formulation from the University of Geneva.

Food for Thought: Crowd-funding – A Useful Financing Strategy for Healthcare Companies?

Crowd-funding is a widely discussed and disputed financing approach these days. It has proven to work in many industries, including the entertainment sector. But what implications will it have for the healthcare industry? Will it have any impact on healthcare at all?

So far, there are only few examples of crowd-funded healthcare ventures. One of them is the Rare Genomics Institute, a US-based non-profit organization dedicated to providing better and faster diagnostics and therapies for rare diseases. They decided for a personalized approach by putting up individual cases of rare disease sufferers on their website and organizing funding for the diagnosis and treatment of the affected patients. Thereby, Rare Genomics Institute provides treatment opportunities for patients who otherwise would not be able to pay their medical bills, as these kind of therapies (and diagnostics) are usually not funded by healthcare providers.

What seems to work as a fundraising approach for individual cases in the US still has to prove its viability in other regions of the world – and in a larger healthcare context. Could expensive drug development eventually be financed by crowd-funding? According to an article in Genetic Engineering News, there is currently not much evidence that biopharmaceutical companies could benefit from crowd-funding, as their financing requirements are significant and long-term oriented. In fact, there are only very few examples of biopharmaceutical companies which have managed to close a financing by crowd-funding, e.g. cancer immune therapy company Urodelia (France). However, the financing volume has not been disclosed. Others, like AMD Therapy (Germany), a fund dedicated to finance the development of novel therapeutics to combat age-related macular degeneration, or Selexel (France), which is developing cancer therapies based on RNA interference, are still raising funds. Interestingly, AMD Therapy aims to raise as much as EUR 60 million by crowd-funding – much more than other biopharma companies in Europe were able to raise by private equity financing during the past 12 months.

At the end of the day, many questions are still unanswered. Will private sponsors continue to be willing to pay a stranger´s medical bills in the long run? Will start-up healthcare companies financed by crowd-funding eventually have to fulfill strict reporting and transparency requirements?


[poll id=”2″]